Cargando…
The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in most cases of warm-antibody AIHA, cold agglutinin disease is treated by targeting the underlying clonal B-cell proliferation or the cl...
Autores principales: | Berentsen, Sigbjørn, Fattizzo, Bruno, Barcellini, Wilma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165002/ https://www.ncbi.nlm.nih.gov/pubmed/37168855 http://dx.doi.org/10.3389/fimmu.2023.1180509 |
Ejemplares similares
-
The Changing Landscape of Autoimmune Hemolytic Anemia
por: Barcellini, Wilma, et al.
Publicado: (2020) -
Cytokine polymorphisms in patients with autoimmune hemolytic anemia
por: Zaninoni, Anna, et al.
Publicado: (2023) -
Diagnosis and Management of Autoimmune Hemolytic Anemias
por: Barcellini, Wilma, et al.
Publicado: (2022) -
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
por: Berentsen, Sigbjørn
Publicado: (2020) -
Bortezomib in autoimmune hemolytic anemia and beyond
por: Pasquale, Raffaella, et al.
Publicado: (2021)